Gilead Sciences, Inc. is a prominent American biopharmaceutical company headquartered in Foster City, California[2]. Founded in 1987 by Michael L. Riordan, the company has grown to become a leader in researching and developing antiviral drugs[2].

## Company Overview

Gilead focuses on creating innovative treatments for life-threatening diseases, with a primary emphasis on:

- HIV/AIDS
- Hepatitis B and C
- Influenza
- COVID-19

The company is known for developing groundbreaking medications such as ledipasvir/sofosbuvir and sofosbuvir[2]. Gilead's commitment to innovation has secured its position as a member of both the Nasdaq-100 and S&P 100 indices[2].

## Historical Milestones

- **1987**: Founded as Oligogen by Michael L. Riordan
- **1992**: Initial public offering
- **2001**: Approval of Viread for HIV treatment
- **2002**: Strategic shift to focus exclusively on antivirals
- **2017**: Acquisition of Kite Pharma, entering the cell therapy market

## Financial Performance

As of the most recent data:

- Stock Symbol: GILD (NASDAQ)
- Share Price: $92.37
- Market Capitalization: $115.12 billion
- Earnings Per Share (EPS): $0.09
- Price-to-Earnings Ratio (P/E): 1026.33

## Global Presence

Gilead Sciences operates internationally, with a significant presence in various countries, including South Korea[3]. The company's global efforts are directed towards:

- Addressing public health threats
- Improving access to medicines
- Combating stigma associated with treatments
- Minimizing environmental impact
- Promoting social justice and reducing healthcare inequalities[3]

Gilead Sciences continues to push the boundaries of medical research, striving to create a healthier world for all people through its pioneering work in virology and expanding impact in oncology[5].

Citations:
[1] https://www.gilead.com
[2] https://en.wikipedia.org/wiki/Gilead_Sciences
[3] https://www.gilead.co.kr
[4] https://consent.yahoo.com/v2/collectConsent
[5] https://kr.linkedin.com/company/gilead-sciences
[6] https://x.com/gileadsciences